Published in J Am Coll Cardiol on June 01, 2000
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol (2007) 1.38
Endothelin. Cell Mol Life Sci (2010) 1.10
A possible role for systemic hypoxia in the reactive component of pulmonary hypertension in heart failure. J Card Fail (2013) 0.84
Endothelin and heart failure. Heart Fail Rev (2001) 0.82
Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Fail Rev (2001) 0.82
Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart (2005) 0.80
Future pharmacologic agents for treatment of heart failure in children. Pediatr Cardiol (2006) 0.78
Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol (2013) 0.78
Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched? Heart Fail Rev (2001) 0.78
Heart failure in 10 years time: focus on pharmacological treatment. Heart (2002) 0.75
Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Fail Rev (2001) 0.75
Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation. J Thorac Dis (2017) 0.75
Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Fail Rev (2001) 0.75
Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem (1999) 6.59
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation (2001) 3.38
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 3.28
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 3.18
Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med (2000) 3.09
Acute heart transplant rejection due to Saint John's wort. Lancet (2000) 2.71
Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 2.69
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest (1990) 2.61
High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation (1997) 2.51
Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension (1986) 2.30
Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation (1998) 2.27
Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 2.05
Diagnostic errors in three medical eras: a necropsy study. Lancet (2000) 2.02
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation (1991) 1.96
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation (2000) 1.93
Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J (1999) 1.83
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol (1990) 1.76
Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience. Eur Heart J (2004) 1.76
Decreased Beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension (1980) 1.69
Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation (1997) 1.67
Endothelial dysfunction in coronary artery disease. Annu Rev Med (1993) 1.64
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol (2000) 1.60
Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol (1998) 1.58
Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther (1982) 1.51
Cyclosporine may affect improvement of cognitive brain function after successful cardiac transplantation. Circulation (1996) 1.51
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension (1990) 1.47
Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. Nephron (1986) 1.47
Predictors of long-term survival after valve replacement for chronic aortic regurgitation; is M-mode echocardiography sufficient? Eur Heart J (2001) 1.47
Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A (2000) 1.47
Endothelin. Key to coronary vasospasm? Circulation (1991) 1.46
Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart (2007) 1.45
Aging, serum estradiol levels, and pregnancy differentially affect vascular reactivity of the rat uterine artery. J Soc Gynecol Investig (2000) 1.44
Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol (2000) 1.43
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol (2000) 1.43
Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation (1990) 1.42
Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation (1993) 1.42
Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormones and inflammatory biomarkers and outcome in patients with chronic heart failure. Int J Clin Pract (2014) 1.41
Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. Eur Heart J (1999) 1.41
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension (1997) 1.41
Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure? Chest (1999) 1.40
Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.40
Images in cardiovascular medicine. Idiopathic hypereosinophilic vasculitis. Circulation (1995) 1.39
[Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions]. Schweiz Med Wochenschr (1997) 1.39
Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res (1999) 1.39
Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Wien Klin Wochenschr (1998) 1.38
Prognosis of medically treated patients referred for cardiac transplantation. Int J Cardiol (1998) 1.38
Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res (2001) 1.36
Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation (2000) 1.35
Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol (1995) 1.34
Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest (1995) 1.34
Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension (1995) 1.34
The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv Ophthalmol (1995) 1.32
Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension (1987) 1.30
Non-invasive beat-to-beat cardiac output monitoring by an improved method of transthoracic bioimpedance measurement. Comput Biol Med (2005) 1.28
Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol (1990) 1.28
Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (1998) 1.26
Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res (1997) 1.25
Compliance in hypertension: facts and concepts. J Hypertens Suppl (1985) 1.25
Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest (2006) 1.23
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 1.22
Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol (2001) 1.22
Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation (1997) 1.22
Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation (1998) 1.20
Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci (1992) 1.19
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation (1999) 1.18
Calcium antagonists in hypertension. J Hypertens Suppl (1987) 1.18
Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol (1997) 1.17
Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension (1996) 1.16
Dark chocolate improves endothelial and platelet function. Heart (2006) 1.15
Importance of endothelium-derived nitric oxide in porcine coronary resistance arteries. Am J Physiol (1991) 1.15
Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res (1991) 1.14
Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci (Lond) (1981) 1.14
Simple renal cyst and hypertension: cause or coincidence? Clin Nephrol (1986) 1.11
The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol (1982) 1.11
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension (1997) 1.10
Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res (1997) 1.09
Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation (1999) 1.08
Synchronous and baroceptor-sensitive oscillations in skin microcirculation: evidence for central autonomic control. Am J Physiol (1997) 1.07
Improvement of thigh muscles by neuromuscular electrical stimulation in patients with refractory heart failure: a single-blind, randomized, controlled trial. Am J Phys Med Rehabil (2001) 1.07
Hyperparathyroidism in congestive heart failure. Am J Med (1998) 1.07
The vasodilator potency of atrial natriuretic peptide in man. Circulation (1987) 1.07
Local anesthetic drugs reduce endothelium-dependent relaxations of porcine ciliary arteries. Invest Ophthalmol Vis Sci (1993) 1.07
Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation (1997) 1.07
Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J (2002) 1.05
Teicoplanin-induced complete AV-block in a heart transplant recipient. Infection (2008) 1.05
Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. J Thromb Haemost (2009) 1.05
Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol (1986) 1.05